Brigatinib
- Generic Name
- Brigatinib
- Brand Names
- Alunbrig
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39ClN7O2P
- CAS Number
- 1197953-54-0
- Unique Ingredient Identifier
- HYW8DB273J
- Background
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal ...
- Indication
The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Brigatinib Before Brain Irradiation Trial (B3i Trial)
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 1
- Registration Number
- NCT04634110
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Conditions
- Interventions
- Drug: Oncology DrugsDrug: ErlotinibDrug: TrastuzumabDrug: Trastuzumab emtansineDrug: PertuzumabDrug: LapatinibDrug: EverolimusDrug: VemurafenibDrug: CobimetinibDrug: AlectinibDrug: BrigatinibDrug: PalbociclibDrug: PonatinibDrug: VismogedibDrug: ItacitinibDrug: IpatasertibDrug: EntrectinibDrug: AtezolizumabDrug: NivolumabDrug: IpilimumabDrug: PemigatinibDrug: PralsetinibDrug: SelpercatinibDrug: TalazoparibDrug: TepotinibDrug: Alpelisib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
- Conditions
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Scott R. Plotkin, MD, PhD
- Target Recruit Count
- 100
- Registration Number
- NCT04374305
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸New York University Langone Medical Center, New York, New York, United States
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
- Conditions
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-10-14
- Target Recruit Count
- 118
- Registration Number
- NCT04318938
- Locations
- 🇩🇪
Universitätsmedizin Essen, Essen, Germany
🇩🇪Evangelisches Krankenhaus Hamm, Hamm, Germany
🇩🇪Lungenklinik Hemer, Hemer, Germany
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Takeda
- Registration Number
- NCT04260009
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
- Conditions
- Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IVB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Recurrent Lung Non-Small Cell CarcinomaStage IVA Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT04227028
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Penn State Cancer Institute, Hershey, Pennsylvania, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
- Conditions
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 33
- Registration Number
- NCT04223596
- Locations
- 🇪🇸
Hospital Regional Universitario de Málaga, Málaga, Andalucia, Spain
🇪🇸Hospital Clínico de Salamanca, Salamanca, Spain
🇪🇸Hospital General de Valencia, Valencia, Spain
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- JI-YOUN HAN
- Target Recruit Count
- 35
- Registration Number
- NCT04074993
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 3
- Registration Number
- NCT04005144
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
- Conditions
- ALK Gene AmplificationAdvanced Malignant NeoplasmALK Gene MutationROS1 Fusion PositiveALK Fusion Protein ExpressionMetastatic Malignant Neoplasm in the BrainLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Neoplasm in the Central Nervous SystemMetastatic Malignant Solid NeoplasmROS1 Gene Amplification
- Interventions
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Sameek Roychowdhury
- Registration Number
- NCT03868423
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.